Delivery Order SPE2DB20D1100-SPE2DB25FE0YK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,725.45 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens (semaglutide) on August 25, 2025, with an ultimate completion date of August 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The place of performance is listed as the...
- The Defense Logistics Agency awarded a $4,030.39 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of September 29, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was awarded through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $5,144.31. This is a firm fixed-price delivery order with an ultimate completion date of August 28, 2025, and represents a non-set-aside, competitively awarded procurement. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections, with a ceiling value of $1,143.87 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery...
- The Defense Logistics Agency awarded a $1,525.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide) on September 2, 2025, with a completion date of September 3, 2025. This non-competitive, non-set-aside delivery order will be fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen (semaglutide injection), a GLP-1 receptor agonist used in diabetes and weight management treatment. This firm fixed-price delivery order, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to...
- The Defense Logistics Agency awarded a $19,682.68 delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 18, 2025. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $15,204.28 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pens (semaglutide injection) with a ceiling value of $1,525.20 and an ultimate completion date of August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), which is valued at $999,999,999 and...
- The Defense Logistics Agency awarded a $6,146.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen (semaglutide injection) with an ultimate completion date of August 4, 2025. This non-set-aside competitive award represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0YKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,025.75 to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen (semaglutide injection) with an ultimate completion date of September 25, 2025. This firm fixed price delivery order represents a non-competitive award and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and other government healthcare systems. The company's portfolio of federal contract awards demonstrates extensive capability in delivering a broad range of pharmaceutical products, including specialty medications, brand-name drugs, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for diabetes management medication aligns with AmerisourceBergen's established role as a primary pharmaceutical supplier within the DLA supply chain, supporting military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 9/24/25 |